Table 4 IR and IRRs for sepsis
From: Optimal statin use for prevention of sepsis in type 2 diabetes mellitus
|  | Events | Person-years | IR (10 000 person-year) | IRR | 95%CI for IRR | P value |
|---|---|---|---|---|---|---|
Statin users | ||||||
 Nonusers | 73,618 | 2,841,369.0 | 259.09 | Ref |  |  |
 Users | 35,866 | 3,382,581.0 | 106.03 | 0.41 | (0.40, 0.41) |  < 0.0001 |
Classes of statins | ||||||
 Nonusers | 73,618 | 2,841,369.0 | 259.09 | Ref |  |  |
 Atorvastatin | 12,279 | 1,219,721.0 | 100.67 | 0.39 | (0.38, 0.40) |  < 0.0001 |
 Lovastatin | 3815 | 228,654.8 | 166.85 | 0.64 | (0.62, 0.67) |  < 0.0001 |
 Simvastatin | 7019 | 672,179.1 | 104.42 | 0.40 | (0.39, 0.41) |  < 0.0001 |
 Fluvastatin | 4032 | 309,680.1 | 130.19 | 0.50 | (0.49, 0.52) |  < 0.0001 |
 Pitavastatin | 44 | 26,126.8 | 16.80 | 0.06 | (0.05, 0.09) |  < 0.0001 |
 Rosuvastatin | 6311 | 665,990.1 | 94.76 | 0.37 | (0.36, 0.38) |  < 0.0001 |
 Pravastatin | 2367 | 260,228.8 | 90.97 | 0.35 | (0.34, 0.37) |  < 0.0001 |
Cumulative dose of statins (cDDD-year) | ||||||
 Nonuser | 73,618 | 2,841,369.0 | 259.09 | Ref |  |  |
 Statin user dose, Q1 | 14,781 | 940,970.8 | 157.08 | 0.61 | (0.6, 0.62) |  < 0.0001 |
 Statin user dose, Q2 | 10,869 | 915,054.6 | 118.78 | 0.46 | (0.045, 0.47) |  < 0.0001 |
 Statin user dose, Q3 | 6724 | 822,236.7 | 81.78 | 0.32 | (0.31, 0.32) |  < 0.0001 |
 Statin user dose, Q4 | 3492 | 704,318.9 | 49.58 | 0.19 | (0.18, 0.20) |  < 0.0001 |